CBLL vs PHG vs QDEL Stock Comparison

Ceribell, Koninklijke Philips and QuidelOrtho Prices as of Nov 16, 2026 Peers: Industry group
CBLL Ceribell, Inc.
$26.42 +5.5% 1M +104.8% 1Y
Market cap
$999.85M
P/E
–
Revenue (TTM)
$108.72M
Div. yield
–
Diagnostic Equipment Healthcare
2 wins
PHG Koninklijke Philips Nv
$30.15 +17.1% 1M +5.2% 1Y
Market cap
$28.39B
P/E
14.9x
Revenue (TTM)
$30.13B
Div. yield
–
Diagnostic Equipment Healthcare
8 wins
QDEL QuidelOrtho Corp
$10.21 -20.9% 1M -52.2% 1Y
Market cap
$679.44M
P/E
–
Revenue (TTM)
$2.59B
Div. yield
–
Diagnostic Equipment Healthcare

Head to Head

10 decided of 12

Koninklijke Philips leads on 8 of the 12 questions below (Koninklijke Philips 8, Ceribell 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCBLLPHGQDELLeader
Larger companyMarket capitalisation $999.85M $28.39B $679.44M PHG
Cheaper on earningsLower P/E, profitable companies only -13.5x 14.9x -1.8x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 15.3x 16.3x PHG
Faster revenue growthRevenue growth, trailing twelve months +31.3% +53.4% -4.5% PHG
More profitableNet margin, trailing twelve months -68.0% 6.3% -14.2% PHG
Better return on capitalReturn on invested capital — 12.1% -2.7% PHG
Less leveragedLower net debt / EBITDA 1.3x 1.7x 8.1x CBLL
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +104.8% +5.2% -52.2% CBLL
Better 5-year returnAnnualised price return, 5 years — -6.1%/yr -41.5%/yr PHG
Less volatileAnnualised volatility, 1 year 51.5% 29.5% 93.2% PHG
Higher overall scoreMean of the five percentile scores vs peers 39/100 80/100 38/100 PHG

Percentile Scorecard

CBLLPHGQDEL

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCBLLPHGQDEL
Valuation 23 #188 of 243 98 #6 of 243 74 #63 of 243
Growth 21 #180 of 228 99 #3 of 228 12 #200 of 228
Profitability 36 #142 of 222 93 #17 of 222 54 #103 of 222
Financial Health 79 #52 of 248 30 #175 of 248 12 #218 of 248
Shareholder Returns 37 #101 of 159 81 #31 of 159 39 #98 of 159
Overall 39 80 38
  • CBLL ranked among 252 companies in Medical Devices and Diagnostics
  • PHG ranked among 252 companies in Medical Devices and Diagnostics
  • QDEL ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCBLLPHGQDELSPY
1 month +5.5%+17.1%-20.9% -3.0%
3 months +8.3%+12.4%-30.0% -4.2%
6 months +59.3%+15.7%-5.8% +0.2%
Year to date +20.5%+11.3%-64.3% +8.5%
1 year +104.8%+5.2%-52.2% +10.1%
3 years —+42.6%-84.6% +64.1%
3 years, per year —+12.6%-46.4% +18.0%
5 years —-27.0%-93.1% +58.1%
5 years, per year —-6.1%-41.5% +9.6%
10 years —+5.3%-53.8% +239.6%
10 years, per year —+0.5%-7.4% +13.0%

Risk

MeasureCBLLPHGQDELSPY
Volatility, 1Y 51.5%29.5%93.2% 13.8%
Downside volatility, 1Y 50.0%27.4%101.0% 14.2%
Beta vs S&P 500, 1Y 1.130.822.57 1.00
Return / volatility, 1Y 2.040.18-0.56 0.74
Max drawdown, 5Y -63.9%-72.2%-94.3% -25.4%
From 52-week high -6.5%-8.4%-71.1% -5.0%
52-week high $28.27$32.91$35.38 $779.14
52-week low $12.89$23.81$9.96 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCBLLPHGQDEL
P/E now vs peer median -13.6xmedian 26.5x 15.1xmedian 26.5x -2.0xmedian 26.5x
P/S now vs peer median 9.3xmedian 2.7x 1.0xmedian 2.7x 0.3xmedian 2.7x
EV/EBITDA now vs peer median -12.3xmedian 18.6x 8.5xmedian 18.6x 10.2xmedian 18.6x
P/FCF now vs peer median -18.0xmedian 25.6x 5.6xmedian 25.6x -6.3xmedian 25.6x
P/B now vs peer median 8.6xmedian 2.5x 2.2xmedian 2.5x 0.4xmedian 2.5x
PEG now vs peer median —median 0.98 0.22median 0.98 0.01median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCBLLPHGQDEL
Revenue $108.72M $30.13B $2.59B
Gross profit $97.04M $16.13B $1.15B
Operating income -$75.87M $2.79B -$127.40M
Net income -$73.88M $1.45B -$369.20M
Free cash flow -$56.43M $5.23B -$117.10M
R&D $25.37M $1.99B $181.90M
EPS (diluted) $-1.92 $1.98 $-5.37
Cash & equivalents $41.99M $3.12B $166.40M
Total debt $21.22M $10.22B $2.94B
Shares (diluted) 38.50M 962.50M 68.70M
Enterprise value $452.67M $16.66B $79.44M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCBLLPHGQDEL
P/E -13.6x 15.1x -2.0x
P/FCF -18.0x 5.6x -6.3x
P/Operating cash flow -18.1x 8.2x 93.3x
P/S 9.3x 1.0x 0.3x
P/B 8.6x 2.2x 0.4x
P/Tangible book 8.6x 2.8x -0.9x
EV/EBITDA -12.3x 8.5x 10.2x
EV/EBIT -12.1x 13.0x -27.5x
EV/Revenue 8.4x 1.2x 1.4x
EV/FCF -16.3x 6.9x -30.0x
EV/Operating cash flow -16.4x 10.2x 444.0x
PEG (3Y EPS CAGR) – 0.22 0.01

Growth

14 metrics
MetricCBLLPHGQDEL
Revenue growth (1Y) 31.3% 53.4% -4.5%
Revenue CAGR (3Y) – 15.1% -6.0%
Gross profit growth (1Y) 33.2% 76.3% -12.2%
Gross profit CAGR (3Y) – 4.0% -9.8%
Operating income growth (1Y) -33.8% 49.6% 84.8%
Operating income CAGR (3Y) – 337.8% -39.0%
Net income growth (1Y) -40.8% 444.3% 68.7%
Net income CAGR (3Y) – 45.2% -210.6%
EPS growth (1Y) -34.6% 177.7% 69.0%
EPS CAGR (3Y) – 69.9% -208.1%
Operating cash flow growth (1Y) -40.0% 154.0% -78.6%
Operating cash flow CAGR (3Y) – 70.2% -72.2%
Free cash flow growth (1Y) -37.8% 74.5% 23.9%
Free cash flow CAGR (3Y) – 39.5% -40.9%

Profitability

14 metrics
MetricCBLLPHGQDEL
Gross margin 89.3% 53.5% 44.2%
EBITDA margin -68.4% 14.1% 13.2%
Operating margin -69.8% 9.2% -4.9%
Pretax margin -68.0% 8.7% -13.0%
Net margin -68.0% 6.3% -14.2%
FCF margin -51.9% 17.4% -4.5%
Operating cash flow margin -51.5% 11.8% 0.3%
Return on equity -60.3% 13.2% -20.7%
Return on assets -46.0% 5.5% -6.4%
Return on invested capital – 12.1% -2.7%
Return on capital employed -52.9% 12.6% -2.7%
Asset turnover 0.7x 1.0x 0.5x
Cash conversion (OCF / net income) 0.8x 2.4x 0.0x
Stock comp / revenue 18.6% 0.5% 1.8%

Financial Health

11 metrics
MetricCBLLPHGQDEL
Debt / assets 13.6% 32.2% 50.8%
Debt / equity 0.2x 0.8x 1.6x
Net debt / EBITDA 1.3x 1.7x 8.1x
Debt / FCF -0.4x 2.0x -25.1x
Liabilities / assets 24.8% 58.7% 69.0%
Equity / assets 75.2% 41.3% 31.0%
Interest coverage -47.4x 6.5x –
Current ratio 8.2x 1.3x 1.4x
Quick ratio 7.6x 0.8x 0.5x
Cash ratio 6.5x 0.4x 0.2x
Altman Z-score 13.25 – 0.27

Shareholder Returns

7 metrics
MetricCBLLPHGQDEL
Dividend yield – 3.3% –
Net buyback yield -0.8% -0.7% -0.6%
Shareholder yield -0.8% 2.5% -0.6%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCBLLPHGQDEL
Forward P/E – 15.3xFY2026 16.3xFY2026
EPS, next fiscal year $-1.96FY2026 $1.99FY2026 $0.66FY2026
EPS growth, next FY – +7.0%FY2026 -68.9%FY2026
EPS growth, the year after – -10.6% +109.1%
Revenue, next fiscal year $118.62MFY2026 $21.44BFY2026 $2.65BFY2026
Revenue growth, next FY +33.2%FY2026 +0.9%FY2026 -2.8%FY2026
Revenue growth, the year after +21.3% -7.8% -1.7%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCBLLPHGQDEL
Held by institutions 79.9% 5.4% 100.0%
Institutions holding 124 365 243
Change in shares held, QoQ +2.2% +0.8% +2.9%
Institutions buying 74 267 143
Institutions selling 36 76 65
Buyers to sellers 2.06 3.51 2.20

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CBLLPHGQDEL
CBLL 1.00 0.22 0.27
PHG 0.22 1.00 0.26
QDEL 0.27 0.26 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CBLL, PHG and QDEL?

Koninklijke Philips (PHG) is the largest by market capitalisation: Ceribell (CBLL) $999.85M, Koninklijke Philips (PHG) $28.39B, QuidelOrtho (QDEL) $679.44M.

Which company is growing faster?

Koninklijke Philips (PHG) grew revenue fastest over the trailing twelve months: Ceribell (CBLL) +31.3%, Koninklijke Philips (PHG) +53.4%, QuidelOrtho (QDEL) -4.5%.

Which company is more profitable?

Koninklijke Philips (PHG) has the highest net margin (Ceribell (CBLL) -68.0%, Koninklijke Philips (PHG) 6.3%, QuidelOrtho (QDEL) -14.2%). On return on invested capital, Koninklijke Philips (PHG) leads (Koninklijke Philips (PHG) 12.1%, QuidelOrtho (QDEL) -2.7%).

Which stock has performed better?

Over the past year Ceribell (CBLL) returned the most: Ceribell (CBLL) +104.8%, Koninklijke Philips (PHG) +5.2%, QuidelOrtho (QDEL) -52.2%. Over five years, Koninklijke Philips (PHG) compounded fastest (Koninklijke Philips (PHG) -6.1%/yr, QuidelOrtho (QDEL) -41.5%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Koninklijke Philips (PHG) has been the steadiest (Ceribell (CBLL) 51.5%, Koninklijke Philips (PHG) 29.5%, QuidelOrtho (QDEL) 93.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CBLL, PHG and QDEL?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Koninklijke Philips (PHG) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.